Our invention is a pharmacological drug candidate to treat COVID-19. Specifically, our findings reveal that CD04872SC is effective in inhibiting the SARSCoV-2 Spike protein binding to the ACE2 receptor; including, its most infectious variants (Delta and Omicron) in functional in vitro assays. Due to the high stability of this antiviral small molecule, we suggest an aerosol-mediated delivery of this potent CD04872SC neutralizer directly to the airway epithelia. This small molecule could be a more efficacious and cost-effective alternative to expensive neutralizing treatments based on monoclonal antibodies.